A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors.

被引：6
|
作者：
Rasco, Drew W.
Li, Yufeng
Tang, Yuefen
Men, Lichuang
Wang, Hengbang
Ji, Jiao
Liang, Zhiyan
Sun, Joan
Amaya, Alex
Huang, Yingjie
Yang, Dajun
Zhai, Yifan
机构：
[1] START, San Antonio, TX USA
[2] Ascentage Pharma Grp Inc, Rockville, MD USA
[3] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[4] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.3125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3125
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
    Xu, Ruihua
    Li, Yuhong
    Ji, Jiao
    Qiu, Miaozhen
    Zhang, Yang
    Liu, Wenqin
    Tian, Xiaohong
    Li, Su
    Wang, Hengbang
    Wang, Fenghua
    Zhang, Dongsheng
    Wang, Feng
    Wang, Zhiqiang
    Luo, Huiyan
    Zou, Benyan
    Wang, De shen
    Ren, Chao
    Jin, Ying
    Zhai, Yifan
    Yang, Dajun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors.
    Rasco, Drew W.
    Lakhani, Nehal J.
    Tang, Yuefen
    Wang, Hengbang
    Ji, Jiao
    Chen, Jason
    Liang, Zhiyan
    Amaya, Alex
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab inpatients with advanced solid tumors: results from two phase I trials
    Liu, F. -R.
    Wei, X. -L.
    Feng, W. -N.
    Zhao, H. -Y.
    Zhang, Y.
    Wang, Z. -Q.
    Zhang, D. -S.
    Wang, F. -H.
    Yang, S.
    Pan, W.
    Men, L.
    Wang, H.
    Liang, E.
    Wang, C.
    Yang, D.
    Zhai, Y.
    Qiu, M. -Z.
    Xu, R. -H.
    ESMO OPEN, 2024, 9 (08)
  • [4] Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors.
    Vaishampayan, Ulka N.
    Fishman, Mayer N.
    Cho, Daniel C.
    Hoimes, Christopher J.
    Velcheti, Vamsidhar
    McDermott, David F.
    Slichenmyer, William J.
    Putiri, Emily
    Losey, Heather
    Rossi, Sean
    Ernstoff, Marc S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
    Rasco, Drew W.
    Lakhani, Nehal J.
    Li, Yufeng
    Men, Lichuang
    Wang, Hengbang
    Ji, Jiao
    Tang, Yuefen
    Liang, Zhiyan
    Amaya, Alex
    Estkowski, Kathy
    Sun, Joan
    Huang, Yingjie
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors.
    Li, Qiang
    Fang, Douglas D.
    Li, Zhe
    Yang, Dajun
    Cao, Fengqi
    Zhai, Yifan
    CANCER RESEARCH, 2021, 81 (13)
  • [7] Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors.
    Jones, S. F.
    Plummer, E. R.
    Burris, H. A.
    Razak, A. R.
    Meluch, A. A.
    Bowen, C. J.
    Williams, D. H.
    Hodge, J. P.
    Dar, M. M.
    Calvert, A. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 85S - 85S
  • [8] Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors.
    Hollebecque, Antoine
    Bahleda, Rastislav
    Thery, Jean Christophe
    Faivre, Laura
    Le Deley, Marie-Cecile
    Paci, Angelo
    Varga, Andrea
    Gazzah, Anas
    Massard, Christophe
    Poinsignon, Vianney
    Malekzadeh, Katty
    Ribrag, Vincent
    Angevin, Eric
    Postel-Vinay, Sophie
    Gomez-Roca, Carlos Alberto
    Gharib, Myriam
    Dufour, Fabienne
    Soria, Jean-Charles
    Spano, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
    Munster, Pamela
    Iannotti, Nicholas
    Cho, Daniel C.
    Kirkwood, John M.
    Villaruz, Liza C.
    Gibney, Geoffrey T.
    Hodi, F. Stephen
    Mettu, Niharika B.
    Jones, Mark
    Bowman, Jill
    Smith, Michael
    Lakshminarayanan, Mani
    O'Day, Steven
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (12): : 2572 - 2584
  • [10] ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.
    Boni, Valentina
    Winer, Ira Seth
    Gilbert, Lucy
    Vaishampayan, Ulka N.
    Rosen, Seth David
    Muzaffar, Jameel
    Spreafico, Anna
    McDermott, David F.
    Chu, Quincy S.
    Dumas, Olivier
    Chauhan, Aman
    Chaudhry, Arvind
    Tomczak, Piotr
    Bruno, Debora S.
    Du, Yangchun
    Bidollari, Ilda
    Rege, Jessicca Martin
    Ernstoff, Marc S.
    Strauss, James F.
    Velcheti, Vamsidhar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345